Literature DB >> 27465979

A prediction model for the response to oral labetalol for the treatment of antenatal hypertension.

D Stott1, M Bolten1, M Salman1, D Paraschiv1, A Douiri2, N A Kametas1,3.   

Abstract

This prospective observational study aimed to identify at presentation the maternal hemodynamic and demographic variables associated with a therapeutic response to oral labetalol and to use these variables to develop a prediction model to anticipate the response to labetalol monotherapy in women with hypertension. It was set at a maternity unit in a UK teaching hospital. Maternal demographic data from 50 pregnant women, presenting with hypertension between January and August 2013, was collected and blood pressure measured with a device validated for pregnancy and pre-eclampsia. Maternal haemodynamics were assessed with a bioreactance monitor. Participants were commenced on oral labetalol, and reviewed until delivery and discharge home. Logistic regression analysis was performed to assess the prediction of response to labetalol according to the maternal demographic and hemodynamic variables. Main outcome measures were the response to labetalol monotherapy up to delivery and discharge home, defined as sustained blood pressure control <140/90, and the rates of severe hypertension. Thirty-seven women (74%) had their blood pressure well controlled with labetalol monotherapy, 13 (26%) failed to achieve control with labetalol alone, of whom 9 developed severe hypertension. Multivariate logistic regression showed that heart rate, ethnicity and stroke volume index were independent predictors of the response to labetalol. The predictive accuracy of the model was 96% (95% confidence interval (CI) 86-99%). Maternal demographics and haemodynamics are potent predictors for the response to labetalol, and these parameters may guide therapy to enable effective blood pressure control and a lowering of severe hypertension rates.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27465979     DOI: 10.1038/jhh.2016.50

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  23 in total

1.  Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial.

Authors:  Ajay K Gupta; Neil R Poulter; Joanna Dobson; Sandra Eldridge; Francesco P Cappuccio; Mark Caulfield; David Collier; J Kennedy Cruickshank; Peter S Sever; Gene Feder
Journal:  Am J Hypertens       Date:  2010-08-19       Impact factor: 2.689

2.  Non-invasive hemodynamic assessment of non-pregnant, healthy pregnant and preeclamptic women using bioreactance. [corrected].

Authors:  Yayoi Ohashi; Hisham Ibrahim; Louis Furtado; John Kingdom; Jose Carlos Almeida Carvalho
Journal:  Rev Bras Anestesiol       Date:  2010 Nov-Dec       Impact factor: 0.964

3.  Hypertension and ethnic group.

Authors:  Morris J Brown
Journal:  BMJ       Date:  2006-04-08

4.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

Review 5.  Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.

Authors:  Edgardo Abalos; Lelia Duley; D Wilhelm Steyn
Journal:  Cochrane Database Syst Rev       Date:  2014-02-06

6.  Less-tight versus tight control of hypertension in pregnancy.

Authors:  Laura A Magee; Peter von Dadelszen; Evelyne Rey; Susan Ross; Elizabeth Asztalos; Kellie E Murphy; Jennifer Menzies; Johanna Sanchez; Joel Singer; Amiram Gafni; Andrée Gruslin; Michael Helewa; Eileen Hutton; Shoo K Lee; Terry Lee; Alexander G Logan; Wessel Ganzevoort; Ross Welch; Jim G Thornton; Jean-Marie Moutquin
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

7.  Validation and compliance of a home monitoring device in pregnancy: microlife WatchBP home.

Authors:  Yealin Chung; Annemarie de Greeff; Andrew Shennan
Journal:  Hypertens Pregnancy       Date:  2009       Impact factor: 2.108

8.  Aldosterone and left ventricular hypertrophy in Afro-Caribbean subjects with low renin hypertension.

Authors:  Andrew D Stewart; Sandrine C Millasseau; Mathew Dawes; Patricia A Kyd; John B Chambers; James M Ritter; Philip J Chowienczyk
Journal:  Am J Hypertens       Date:  2006-01       Impact factor: 2.689

9.  Value of noninvasive hemodynamics to achieve blood pressure control in hypertensive subjects.

Authors:  Ronald D Smith; Pavel Levy; Carlos M Ferrario
Journal:  Hypertension       Date:  2006-03-06       Impact factor: 10.190

10.  General conditions for predictivity in learning theory.

Authors:  Tomaso Poggio; Ryan Rifkin; Sayan Mukherjee; Partha Niyogi
Journal:  Nature       Date:  2004-03-25       Impact factor: 49.962

View more
  2 in total

1.  Study protocol for the randomized controlled EVA (early vascular adjustments) trial: tailored treatment of mild hypertension in pregnancy to prevent severe hypertension and preeclampsia.

Authors:  Eva Mulder; Chahinda Ghossein-Doha; Evine Appelman; Sander van Kuijk; Luc Smits; Rogier van der Zanden; Joris van Drongelen; Marc Spaanderman
Journal:  BMC Pregnancy Childbirth       Date:  2020-12-12       Impact factor: 3.007

2.  Pregnancy hypertension diagnosis and care in COVID-19 era and beyond.

Authors:  L A Magee; A Khalil; P von Dadelszen
Journal:  Ultrasound Obstet Gynecol       Date:  2020-07       Impact factor: 8.678

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.